U.S. Pharmaceuticals & Biotech Potentially Undervalued Small Caps

Biofrontera

Market Cap: US$14.0m

A biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.

TScan Therapeutics

Market Cap: US$59.8m

A clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States.

Traws Pharma

Market Cap: US$10.2m

A clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer.

Pharma-Bio Serv

Market Cap: US$11.5m

Operates as a regulatory affair, compliance, and technology transfer services consulting firm in Puerto Rico, the United States, Europe, Brazil, and internationally.

aTyr Pharma

Market Cap: US$50.0m

A clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States.

Grace Therapeutics

Market Cap: US$40.2m

Engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.

Bioqual

Market Cap: US$29.1m

Provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States.

Cardiff Oncology

Market Cap: US$60.2m

A clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States.

Mereo BioPharma Group

Market Cap: US$49.5m

A biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States.